Citeline is part of the Business Intelligence Division of Informa PLC
Copyright 2015 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ( “Informa”) whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Our extensive team of trial experts and analysts tracks over 30,000 information sources, delivering a unique combination of reliable data and unlimited personal research support.
Citeline covers every stage of drug development, featuring over 180,000 drug trials across 150 countries and more than 180 diseases.
Our PhD and MSc-level analysts conduct support research on your behalf at no additional cost, helping you to gain deeper competitive pharma business intelligence on specific trials within just 48 hours.
Citeline examines over 322,000 clinical trial investigators, assessing their ability as well as their expertise in specific pharmaceutical clinical trials, giving you access to the most extensive dataset of investigator expertise, experience and capacity.
Citeline has designed proprietary pharmaceutical clinical trial algorithms to help you better predict clinical trial timelines, from patient enrollment through study duration period and trial completion.
The full suite of Citeline pharmaceutical clinical trial products has been developed to allow easy cross-navigation, allowing you to move seamlessly from pipeline analysis and drug trial records to profiles of clinical trial investigators.
The two furthest developed PCSK9 inhibitors have had very similar clinical development timelines. Sanofi and Regeneron’s alirocumab and Amgen’s evolocumab both began Phase III studies in January 2012 and both received their first regulatory appro
This analysis provides a five year review of the RA kinase inhibitor programs – where have they been and where are they going
The usual concerns surrounding patent expiries, merger and acquisition activity, pricing issues and high R&D costs appear to be being held at bay by the surging size of the R&D pipeline and the record-breaking year for new drug introductions,
The Citeline family of pharmaceutical clinical trial intelligence products.